Locations:
Search
Four genomic clusters identified
Cael-101 + CyBorD dosing and outcomes
A major advance in prognosis for myelodysplastic syndromes that may improve outcomes
Molecular markers could potentially predict major adverse side effects
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Multi-institutional registry analysis highlights need for further research
Working from home leads to more efficiency, job satisfaction for research coordinators
35-year-old presents with suspected iris melanoma
Nivolumab, CV301 and systemic chemotherapy trial
Preclinical studies point to antitumor activity of the ERM inhibitor NSC668394
Treatment based on next generation sequencing shows promise
Advertisement
Advertisement